CRISPR Therapeutics (CRSP) vs ImmunityBio (IBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ImmunityBio (IBRX) has outperformed CRISPR Therapeutics (CRSP) over the past year, gaining 189.4% versus a loss of 22.2%. Over five years, IBRX leads with a -7.4% price change compared with -50.4% for CRSP. ImmunityBio is the larger company by market cap ($6.40 billion vs $3.79 billion), about 1.7 times the size.
ImmunityBio converts more of its revenue into profit, with a net margin of -310.2% versus -16569.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRSP | IBRX |
|---|---|---|
| Share price | $39.10 | $6.02 |
| Market cap | $3.79B | $6.40B |
| 1-day change | +0.44% | -8.37% |
| YTD return | -25.44% | +204.04% |
| 1-year return | -22.16% | +189.42% |
| 5-year return | -50.37% | -7.38% |
| EPS (TTM) | $-4.73 | $-1.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.51M | $113.29M |
| Revenue growth (YoY) | -90.59% | +668.31% |
| Net income (latest FY) | $-581.60M | $-351.40M |
| Gross margin | — | 99.34% |
| Operating margin | -18933.65% | -226.00% |
| Net margin | -16569.77% | -310.18% |
| 52-week high | $63.45 | $12.43 |
| 52-week low | $38.15 | $1.95 |
| Distance from 52-week high | -38.38% | -51.57% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +118.47% | +136.71% |
| Average volume | 1.74M | 12.97M |
| Shares outstanding | 97.00M | 1.06B |
| Employees | — | 684 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBRX has outperformed CRSP by 211.6 percentage points over the past year.
- ImmunityBio is more profitable, keeping -310.2 cents of every revenue dollar as net income versus -16569.8 cents for CRISPR Therapeutics.
- ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs -90.59%).
About CRISPR Therapeutics
CRSP stock →CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
CRSP vs IBRX FAQ
Which is bigger, CRISPR Therapeutics or ImmunityBio?
ImmunityBio (IBRX) is larger, with a market capitalization of $6.40B compared with $3.79B for CRISPR Therapeutics (CRSP).
Which stock has performed better over the past year, CRSP or IBRX?
IBRX returned +189.42% over the past 12 months, compared with -22.16% for CRSP (price return, excluding dividends). Past performance does not predict future results.
Are CRISPR Therapeutics and ImmunityBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.